Is “cosmeceutical” a real FDA category, and can the word turn my cosmetic into a drug?

No. “Cosmeceutical” is a marketing term, not a legal category. FDA recognizes only two categories for these products: cosmetics and drugs. What decides which one your product is isn’t the word on the box — it’s the claims you make. Say the product beautifies and it is a cosmetic. Say it changes the structure or function of the skin and it is a drug, and an unapproved one.

What does FDA actually recognize?

Under the Federal Food, Drug, and Cosmetic Act, a cosmetic is a product intended to cleanse, beautify, promote attractiveness, or alter appearance. A drug is a product intended to affect the structure or function of the body, or to diagnose, cure, treat, or prevent a disease. “Cosmeceutical” appears nowhere in the statute. FDA has stated repeatedly that no such category exists.

What moves a product from cosmetic to drug?

Claims do. If your label, website, social posts, or promotional materials say the product “stimulates collagen synthesis,” “repairs DNA damage,” “inhibits melanin production,” or “blocks DHT,” you have made a drug claim. FDA looks at the overall impression of your marketing, not just the fine print. A product with a cosmetic ingredient list can still be an unapproved drug if its claims cross the line.

Where do skincare brands slip most often?

The most common errors are using clinical-sounding language (“clinically proven to reduce wrinkles”), mechanism-of-action claims (“activates skin’s natural repair process”), disease references (“for rosacea-prone skin”), and repurposed drug studies cited on a cosmetic product page. Influencer scripts and customer review reposts you amplify carry the same risk as your own copy.

What is the actual consequence?

A product FDA determines is an unapproved new drug is subject to enforcement action, including Warning Letters, import alerts, seizure, and injunction. Retailers and marketplaces conduct their own audits and can delist a product without waiting for FDA. A Warning Letter becomes part of the public record and can follow a brand into investor due diligence and acquisition reviews.

What should a skincare brand do about it?

Audit every claim touchpoint — label, DTC site, Amazon listing, paid ads, influencer briefs, and press releases. Rewrite drug claims as appearance-based claims: “reduces the look of fine lines” instead of “reduces fine lines.” Have your claim inventory reviewed by regulatory counsel before you launch or relaunch, not after you receive a Warning Letter.

Frequently asked questions

Is it illegal to use the word “cosmeceutical”?

The word itself isn’t prohibited, but it has no legal meaning and it frames your product as drug-like, which can attract FDA scrutiny of your claims.

Can a product be both a cosmetic and a drug?

Yes. Sunscreens, anti-dandruff shampoos, and fluoride toothpastes are common examples. Each must meet both sets of requirements.

Does a disclaimer like “not intended to treat any condition” fix a drug claim?

Generally no. FDA evaluates the overall impression of the labeling, and a disclaimer does not erase a drug claim made elsewhere on the product.

What about claims made by influencers or in customer reviews we repost?

Content you commission, script, or republish can be treated as your claim. Third-party testimonials you amplify may carry the same regulatory weight as your own statements.

Does MoCRA change any of this?

MoCRA added registration, listing, safety substantiation, and serious adverse event reporting requirements for cosmetics, but did not create a cosmeceutical category or change the cosmetic-versus-drug analysis.

Talk to an FDA compliance attorney before a claim becomes a warning letter, a recall, or a delisted SKU. Contact Capote Law Firm today.